Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine Inc (NASDAQ: EDIT), a leader in CRISPR-based genome editing, provides this centralized hub for tracking all corporate developments and scientific advancements. Access real-time updates on clinical trial progress, regulatory milestones, and financial disclosures essential for monitoring this pioneering biotech firm.
This resource aggregates EDIT's press releases, partnership announcements, and peer-reviewed research findings. Investors will find critical updates on pipeline therapies for genetic disorders, while analysts gain insights into strategic initiatives shaping the genomic medicine landscape. Content spans quarterly earnings, intellectual property developments, and preclinical breakthroughs.
Key categories include therapy authorization updates, collaboration agreements with research institutions, and presentations at major medical conferences. All materials are sourced directly from Editas Medicine and verified financial filings to ensure reliability.
Bookmark this page for efficient tracking of EDIT's progress in developing CRISPR/Cas9 and Cas12a therapies. Check regularly for authoritative updates on one of biotech's most innovative gene-editing platforms.
Editas Medicine, Inc. (Nasdaq: EDIT) announced its presentation of preclinical data on cell therapy for cancer treatment at the SITC 36th Annual Meeting held from November 10-14, 2021. The data showcases a new method for high-level CD16 expression in iPSC-derived natural killer cells, demonstrating enhanced cytotoxic activity against tumor cells. The poster presentation is scheduled for November 12, 2021. Editas focuses on developing transformative genomic medicines using CRISPR technology to address serious diseases.
Editas Medicine will present at Chardan’s 5th Annual Genetic Medicines Conference on October 4, 2021, at 8:30 a.m. ET. Attendees can access a live webcast through the Investors section of the Editas Medicine website, with an archived replay available for 30 days post-event.
Editas Medicine focuses on delivering transformative genomic medicines utilizing CRISPR technology to treat serious diseases globally. For more details, visit www.editasmedicine.com.
Editas Medicine has released positive initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101, an experimental treatment for blindness due to Leber congenital amaurosis 10 (LCA10).
Notable findings include a favorable safety profile observed over 15 months with no serious adverse events and signs of efficacy in the mid-dose cohort, showing visual improvements and successful gene editing.
The trial continues with adult high-dose and pediatric mid-dose cohorts, offering hope for patients with this rare genetic disorder.
Editas Medicine (NASDAQ: EDIT) announced the appointment of Emma Reeve to its Board of Directors. With over 25 years of experience in the biopharmaceutical sector, Reeve brings a strong financial background, previously serving as CFO at Constellation Pharmaceuticals and holding senior roles at major firms like Bristol-Myers Squibb and Merck. Reeve’s addition aims to enhance Editas's operational effectiveness and fundraising capabilities as the company continues advancing its pipeline and technologies for genome editing.
Editas Medicine (Nasdaq: EDIT) announced that an abstract with initial clinical data from the BRILLIANCE trial of EDIT-101 has been selected for oral presentation at the RD2021 symposium. This event will take place on September 29, 2021, in Nashville, Tennessee. The BRILLIANCE trial evaluates EDIT-101 for Leber congenital amaurosis 10 (LCA10), targeting safety and efficacy through a gene-editing approach. The presentation will cover patient safety assessments and preliminary analysis of secondary endpoints, with further details available during a webcast following the presentation.
Editas Medicine, a leader in genome editing, will participate in two upcoming investor conferences. The Wells Fargo 2021 Virtual Healthcare Conference is scheduled for September 10, 2021 at 8:00 a.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021 at 9:30 a.m. ET. Both events will be available via live webcast on the company's website, with archived recordings accessible for about 30 days.
Editas focuses on developing CRISPR-based genomic treatments for serious diseases worldwide.
Editas Medicine, Inc. (Nasdaq: EDIT) presented new data on its innovative gene editing technology, SLEEK, at the Cold Spring Harbor Laboratory's Genome Engineering meeting. SLEEK achieves high efficiencies in multi-transgene knock-in across various cell types, including iPSCs, T cells, and NK cells, with over 90% efficiency reported. This advancement positions SLEEK as a promising strategy for developing next-generation cell therapies for serious diseases, particularly cancer. Additionally, Editas shared its CALITAS algorithm for identifying potential off-target sites, enhancing its commitment to advancing gene editing technologies.
Editas Medicine (Nasdaq: EDIT) made significant advancements in its clinical trials for gene-editing therapies. The BRILLIANCE trial for EDIT-101 is enrolling pediatric and adult high-dose cohorts, with initial data expected in September 2021. The RUBY trial for EDIT-301, targeting sickle cell disease, is also progressing, with the first patient expected to be dosed by year-end. Financially, Editas reported a net loss of $55.3 million for Q2 2021, an increase from $23.6 million in Q2 2020. Cash reserves stood at $698.1 million, sufficient to fund operations into 2023.
Editas Medicine, Inc. (Nasdaq: EDIT) and Integrated DNA Technologies (IDT) announced a research publication showcasing the advantages of Alt-R™ A.s. Cas12a (Cpf1) Ultra, an engineered nuclease. The findings, published in Nature Communications, reveal a significant improvement in gene editing efficiency and specificity compared to existing tools like SpCas9. This proprietary nuclease demonstrates near 100% editing efficiency across various cell lines and could lead to novel therapies for genetic diseases and engineered cell treatments for cancer.
Editas Medicine, a genome editing leader, will host a conference call and webcast on August 4, 2021, at 8:00 a.m. ET. The purpose is to update stakeholders on corporate developments and Q2 2021 results. U.S. participants can join by dialing 877-407-0989, while international callers can dial 201-389-0921. A live webcast will be accessible on the company's website.
Editas focuses on innovative CRISPR/Cas9 and CRISPR/Cas12a technologies to develop genomic therapies targeting serious diseases globally.
FAQ
What is the current stock price of Editas Medicine (EDIT)?
What is the market cap of Editas Medicine (EDIT)?
